Hemodynamic monitoring company Lidco said Friday it had won a contract from a public university medical centre in Southern California. The customer had signed a five-year agreement for 15 monitors, converting from their current hemodynamic monitoring provider, the company said. The centre was recognised as a thought leader in the US in the treatment of Sepsis - the leading cause of death in hospitals and re-admissions. Lidco's technology had been 'strongly associated with successful treatment protocols for this patient population and there are a number of clinical papers demonstrating the benefits of using LiDCO technology within this patient group,' the company added. High Usage Programme (HUP) business model continued to build momentum in the US. This 'greatly enhancing revenue visibility and reduces the challenges of closing orders around the year-end,' the company said. At 8:57am: (LON:LID) LiDCO Group PLC share price was +0.05p at 3.6p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.